TrialBlood neoplasia2025
Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4
Elizabeth A Griffiths et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it